Central GPR55 may prevent nicotine reinforcing actions: a preliminary study

Area of Science:

• Neuroscience
• Pharmacology
• Receptor Biology

Background:

• GPR55 is an orphan receptor with endogenous agonists including lysophosphatidylinositol (LPI) and N‑acetylethanolamides (NAEs) like palmitoylethanolamide (PEA) and anandamide.
• GPR55 plays a role in central nervous system functions such as motor coordination, memory, pain, and anxiety.
• Previous research suggests GPR55/GPR18 involvement in brain reward systems, as indicated by studies on the effects of O-1602 on morphine and nicotine reinforcement.

Purpose of the Study:

• To investigate the pharmacological effects of endogenous and synthetic GPR55 ligands on the reinforcing properties of nicotine.
• To explore the potential role of GPR55 in modulating nicotine's effects within the conditioned place preference (CPP) paradigm.

Main Methods:

• Utilized the conditioned place preference (CPP) paradigm to assess the reinforcing effects of nicotine.
• Administered endogenous GPR55 agonists (LPI, PEA), a synthetic agonist (ML184), and a selective antagonist (ML193) in conjunction with nicotine.
• Observed the impact of these GPR55 modulators on the behavioral changes induced by nicotine.

Main Results:

• Injections of LPI, PEA, ML184, and ML193 interfered with the nicotine-induced change in place preference.
• These findings suggest that GPR55 activation or antagonism can alter the reinforcing effects of nicotine.

Conclusions:

• GPR55 ligands, including both agonists and antagonists, significantly impact the reinforcing actions of nicotine in the CPP paradigm.
• The precise mechanisms underlying GPR55's influence on nicotine reinforcement require further investigation, potentially involving central GPR55 pathways.